A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
National Cancer Institute (NCI)
OncoC4, Inc.
University of Florida
DualityBio Inc.
University of Nebraska
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Elicio Therapeutics
University Hospital, Ghent
Pfizer
Tempus AI
Elevation Oncology
Taproot Health
Carisma Therapeutics Inc
Beijing Biostar Pharmaceuticals Co., Ltd.
UTC Therapeutics Inc.
Celldex Therapeutics
Centro di Riferimento Oncologico - Aviano
Klus Pharma Inc.
Xencor, Inc.
MacroGenics
Karolinska University Hospital
SpeciCare
Abramson Cancer Center at Penn Medicine
Canadian Cancer Trials Group
Swiss Cancer Institute
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
National Institutes of Health Clinical Center (CC)
Roger Williams Medical Center
National Cancer Institute (NCI)
NYU Langone Health